Healthtech and Digital Health Investors
A verified directory of 288 digital health investors — sorted by the reimbursement path they underwrite and how much regulatory risk they will take.
Last verified
- 288
- Healthtech investors
- 149
- Firms
- 25%
- Fund pre-clearance risk
- 91%
- Reachable
Verified in the last 30 days
With a live digital health thesis
Will write before an FDA decision
At least one verified contact path
Free preview
6 of 288 profiles
Names, roles, companies and live signals are public. Verified emails and LinkedIn URLs stay masked until you sign in.
- 01
Yolanda Featherstone-Ige
General Partner · Marlstone Health Partners
Back Bay, Boston
Six provider-paid deals in twelve months; leads at seed and takes the board seat.
- Provider-paid
- Dedicated health fund
- Leads
- High volume
- y•••••@marlstonehealth.vc Locked
- 02
Ravindra Ottosson-Nair
Partner · Culvert Bay Capital
Flatiron, New York
Explicitly will not fund anything requiring FDA clearance; passed on nine device deals last year.
- Avoids FDA
- Employer channel
- Narrow mandate
- Fast no
- r•••••@culvertbay.capital Locked
- linkedin.com/in/•••••• Locked
- 03
Perpetua Nakashima-Vaal
Managing Director · Ridgewell Health Ventures
Nashville, TN
Runs a 14-hospital system's venture arm; every cheque comes with a pilot inside the parent.
- Health-system arm
- Provider-paid
- Pilot attached
- Strategic
- p•••••@ridgewellhv.com Locked
- linkedin.com/in/•••••• Locked
- 04
Callum Adebowale-Frisk
Principal · Ostmark Value Partners
Minneapolis, MN
Underwrites on actuarial models only; wants PMPM savings before a product demo.
- Payer and VBC
- Dedicated health fund
- Actuarial diligence
- Leads
- c•••••@ostmarkvalue.com Locked
- linkedin.com/in/•••••• Locked
- 05
Isolde Mwangi-Trevanion
Angel Investor · Independent
Hyde Park, Chicago
Practising anaesthesiologist; three first cheques this year, each followed by a service-line intro.
- Clinician angel
- Regulated device
- First cheque
- Opens doors
- i•••••@isoldemt.health Locked
- linkedin.com/in/•••••• Locked
- 06
Thaddeus Okonkwo-Lindgren
Investment Director · Brayfield Life Sciences Fund
South San Francisco, CA
Pharma-backed vehicle; opened a $60M tools mandate in February and has deployed twice.
- Pharma CVC
- Life sciences tools
- New mandate
- Deploying
- t•••••@brayfieldlsf.com Locked
- linkedin.com/in/•••••• Locked
Unlock the full Healthtech Investors list
The other 282 profiles are in Articuler. A free account runs 3 directory matches a day — every match returns full profiles with verified emails and LinkedIn URLs. Upgrade for unlimited matches, filtering and export.
Sign in to unlock the full listFree account · No credit card · Takes about 30 seconds
Opens Articuler search for “Investors backing digital health and healthtech startups”
Frequently asked questions
- What is the single question that decides whether a healthtech investor can back me?
- Who pays. An investor whose portfolio is provider-paid software has underwriting comparables for hospital sales cycles and none for a benefits-channel business, and the reverse is equally true. 82 of these are provider-paid and 39 are employer-channel; a pitch that crosses that line usually dies in the second meeting rather than the first, which is the expensive way to learn it.
- How many will look at a company before it has clearance?
- 71, a quarter of the list. The other three quarters split between wanting a cleared or exempt product in hand and avoiding regulated pathways as a category. If you are pre-submission, the practical population is much smaller than the headline number suggests, and it is worth targeting it deliberately rather than working down a general list.
- Are health-system venture arms worth approaching?
- 34 are listed and they behave unlike financial funds. The cheque often arrives attached to a pilot inside the parent system, which is either the most valuable thing in your first year or a distraction that shapes the product around one customer. Both outcomes are common enough that it is worth deciding which you are signing up for before the term sheet.
- What does a clinician syndicate actually add?
- The 35 operator angels and clinician syndicates rarely lead, but they open doors that no amount of outbound will. A cardiologist angel introducing you to a service-line chief skips the layer that stops most healthtech sales. Their cheques are small; treat them as distribution rather than capital.
- Does the payer and value-based care group invest differently?
- They diligence differently. The 54 in that bucket will want actuarial logic — cost avoided per member per month, and who books the saving — long before they care about the interface. Founders who arrive with a product demo and no unit economics story tend to get a polite pass from this group specifically.
- How current is this and what falls out of it?
- It is refreshed on a rolling 30-day cycle, last passed on 15 August 2026. Partners who have not written a digital health cheque in eighteen months drop out even if the firm's website still lists a health practice, because a stale thesis produces meetings that cannot end in a term sheet.